Pharmaceutical Executive October 9, 2024
Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
In 2025, artificial intelligence (AI) will be at the center of business strategy with huge investments, especially in life sciences. Over time, AI will reduce the cycle length and failure rate in scientific research and critical drug discovery areas, thus significantly lower the dollars per drug approved.
One report shows that the life sciences market size for AI investment is expected to reach nearly $10 billion before 2032.1 Bain and Company reports that 40% of pharma companies are including anticipated...
Today's Sponsors
Today's Sponsor